Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.

Aplastic anemia Atypical thrombosis Flow cytometry Hemolytic anemia Myelodysplastic syndromes Paroxysmal nocturnal hemoglobinuria

Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
May 2019
Historique:
received: 03 11 2017
accepted: 24 02 2019
pubmed: 15 3 2019
medline: 26 4 2019
entrez: 15 3 2019
Statut: ppublish

Résumé

In this study, we aimed at disclosing the main features of paroxysmal nocturnal hemoglobinuria (PNH) clones, their association with presentation syndromes, and their changes during follow-up. A large-scale, cooperative collection (583 clones from 529 patients) of flow cytometric and clinical data was entered into a national repository. Reason for testing guidelines were provided to the 41 participating laboratories, which followed the 2010 technical recommendations for PNH testing by Borowitz. Subsequently, the 30 second-level laboratories adopted the 2012 guidelines for high-resolution PNH testing, both upon order by the local clinicians and as an independent laboratory initiative in selected cases. Type3 and Type2 PNH clones (total and partial absence of glycosyl-phosphatidyl-inositol-anchor, respectively) were simultaneously present in 54 patients. In these patients, Type3 component was sevenfold larger than Type2 (p < 0.001). Frequency distribution analysis of solitary Type3 clone size (N = 442) evidenced two discrete patterns: small (20% of peripheral neutrophils) and large (> 70%) clones. The first pattern was significantly associated with bone marrow failure and myelodysplastic syndromes, the second one with hemolysis, hemoglobinuria, and thrombosis. Pediatric patients (N = 34) showed significant preponderance of small clones and bone marrow failure. The majority of PNH clones involved neutrophils, monocytes, and erythrocytes. Nevertheless, we found clones made exclusively by white cells (N = 13) or erythrocytes (N = 3). Rare cases showed clonal white cells restricted only to monocytes (6 cases) or neutrophils (3 cases). Retesting over 1-year follow-up in 151 cases showed a marked clone size increase in 4 cases and a decrease in 13, demonstrating that early breaking-down of PNH clones is not a rare event (8.6% of cases). This collaborative nationwide study demonstrates a clear-cut difference in size between Type2 and Type3 clones, emphasizes the existence of just two classes of PNH presentations based on Type3 clone size, depicts an asymmetric cellular composition of PNH clones, and documents the possible occurrence of changes in clone size during the follow-up.

Identifiants

pubmed: 30868306
doi: 10.1007/s00277-019-03644-8
pii: 10.1007/s00277-019-03644-8
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1083-1093

Auteurs

Elisa Cannizzo (E)

Servizio Medicina Trasfusionale ed Ematologia, ASP 7, Ragusa, Italy.

Maddalena Raia (M)

CEINGE Biotecnologie Avanzate, Naples, Italy.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy.

Maria Stefania De Propris (MS)

Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy.

Anna Triolo (A)

Ematologia e Trapianto di Midollo Osseo, P.O. Ferrarotto, AOU Vittorio Emanuele, Catania, Italy.

Barbara Scarpati (B)

Servizio di Immunologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Anna Marfia (A)

Divisione di Ematologia, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.

Alessandra Stacchini (A)

UOC Anatomia Patologica Generale e Oncogenetica Molecolare, PO Molinette, AOU Città della Salute e della Scienza, Torino, Italy.

Francesco Buccisano (F)

UOC Ematologia, Università Tor Vergata, Rome, Italy.

Francesco Lanza (F)

UO di Ematologia, Istituti Ospitalieri, Cremona, Italy.

Antonio Regazzoli (A)

Laboratorio Analisi, AO Spedali Civili, Brescia, Italy.

Angela Michelutti (A)

Divisione di Ematologia e Trapianto di Midollo, AOU Udine, Udine, Italy.

Simone Cesaro (S)

Oncoematologia Pediatrica, AOU Verona, Verona, Italy.

Cinzia Armentano Conte (CA)

Divisione di Ematologia e Trapianto Cellule Staminali, AO San Camillo, Rome, Italy.

Laura Vanelli (L)

Dip Oncoematologico, IRCCS S. Matteo, Pavia, Italy.

Elisabetta Tedone (E)

UOC Ematologia2, AOU S. Martino, Genoa, Italy.

Paola Omedè (P)

Lab Citometria, UOC Ematologia, AOU Città della Salute e della Scienza, Torino, Italy.

Maria Matilde Ciriello (MM)

Laboratorio Analisi, AO SS. Antonio e Biagio, Alessandria, Italy.

Roberto Caporale (R)

Area Diagnostica di Laboratorio, Dip Servizi, AOU Careggi, Florence, Italy.

Virginia Catinella (V)

UOC Immunoematologia e Centro Trasfusionale, AO S Spirito, Pescara, Italy.

Giorgia Pantano (G)

Dipartimento Interaziendale Medicina di Laboratorio, Policlinico Universitario, Padova, Italy.

Clorinda De Rosa (C)

Lab Citometria, UOC Medicina, Ente Ecclesiastico Ospedale F. Miulli, Acquaviva delle Fonti, Italy.

Catia Lo Pardo (C)

Centro Trasfusionale, AORN Cardarelli, Naples, Italy.

Giovanni Poletti (G)

Laboratorio Ematologia, Laboratorio AVR, Pievesestina, Italy.

Francesca Ulbar (F)

Laboratorio di Immunologia, Istituto di Ematologia L. & A. Seràgnoli, AOU S.Orsola-Malpighi, Bologna, Italy.

Maria Cristina Pavanelli (MC)

SS Citometria a flusso, UOC Anatomia Patologica, PO S. Andrea, Vercelli, Italy.

Laura Del Pup (L)

Laboratorio di Ematologia, Servizio Immunotrasfusionale, Ospedale Civile Ca' Foncello, Treviso, Italy.

Virginia Ottaviano (V)

Laboratorio di Citofluorimetria, UO di Ematologia Universitaria AOUP, Pisa, Italy.

Anna Maria Santonocito (AM)

UOC Ematologia con Laboratorio di Biologia Molecolare, PO San Vincenzo, Taormina, Italy.

Chiara Bartocci (C)

Dipartimento Ospedaliero di Medicina Interna, AOU Ospedali Riuniti, Ancona, Italy.

Elisa Boscaro (E)

Dipartimento di Medicina, Ematologia e Immunologia Clinica Policlinico Universitario, Padova, Italy.

Marcella Arras (M)

CTMO, PO Binaghi, ASL, Cagliari, Italy.

Rachele Amodeo (R)

Sezione di Citometria, UOC Diagnostica di laboratorio, AO S. Andrea, Università La Sapienza, Rome, Italy.

Anna Mestice (A)

Dipartimento Ematologia con Trapianto, AOU Policlinico, Bari, Italy.

Bianca Oliva (B)

UOC Patologia Clinica, AO Bianchi Melacrino Morelli, Reggio Calabria, Italy.

Luisa Ferrari (L)

Lab Ematologia, AOU, Ferrara, Italy.

Teodora Statuto (T)

Direzione Scientifica, IRCCS CROB, Rionero in Vulture, Italy.

Fiorella D'Auria (F)

Direzione Scientifica, IRCCS CROB, Rionero in Vulture, Italy.

Graziano Pianezze (G)

Ematologia, Ospedale S Martino, Belluno, Italy.

Donatella Tanca (D)

Settore Ematologia, Citometria e Coagulazione, Ospedale Lavagna, ASL 4 Chiavarese, Lavagna, Italy.

Feliciano Visconte (F)

CEINGE Biotecnologie Avanzate, Naples, Italy.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy.

Fabiana Rubba (F)

DAI Sanità Pubblica, AOU Federico II, Naples, Italy.

Pellegrino Musto (P)

Direzione Scientifica, IRCCS CROB, Rionero in Vulture, Italy.

Massimo Geuna (M)

Laboratorio di Patologia Oncoematologica, Anatomia Patologica, AO Ordine Mauriziano, Torino, Italy.

Arianna Gatti (A)

Hematology Laboratory and Transfusion Center, Western Milan Area Hospital Consortium, Legnano General Hospital, 20025, Legnano, Milan, Italy.

Bruno Brando (B)

Hematology Laboratory and Transfusion Center, Western Milan Area Hospital Consortium, Legnano General Hospital, 20025, Legnano, Milan, Italy. bruno.brando@asst-ovestmi.it.

Luigi Del Vecchio (L)

CEINGE Biotecnologie Avanzate, Naples, Italy.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy.
DAI Medicina Trasfusionale, AOU Federico II, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH